Akero Therapeutics Faces Critical Deadline Amid Acquisition Scrutiny
Published on 11/18/2025 at 09:24 | Redaktion boerse-global.de
Investors in Akero Therapeutics are bracing for a pivotal moment as the biopharmaceutical company approaches a decisive regulatory deadline. With the proposed acquisition by Novo Nordisk entering its final phase, the situation has grown increasingly complex due to legal investigations and disappointing financial performance.
The timeline for Novo Nordisk’s $5.2 billion acquisition offer reaches a crucial milestone on December 5, 2025, when the mandatory waiting period under the Hart-Scott-Rodino Act expires. This deadline requires U.S. antitrust authorities to issue their verdict on the proposed transaction. The acquisition terms include $54 per share in cash plus an additional $6 per share contingent value right, dependent on regulatory approval of the drug candidate Efruxifermin by 2031.
Complicating Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
